Overexpression of CISD1 Predicts Worse Survival in Hepatocarcinoma Patients

Table 1

Correlation of CISD1 mRNA expression and clinical prognosis in liver cancer with different clinicopathological factors by the Kaplan-Meier plotter.

Clinicopathological characteristics	Overall survival ()			Progression-free survival ()
		Hazard ratio	value		Hazard ratio	value
Sex
Female	121	0.66 (0.37-1.17)	0.15	121	0.86 (0.49-1.49)	0.58
Male	250	1.85 (1.19-2.88)	0.0059	250	1.49 (1.03-2.15)	0.032
Stage
I+II	257	1.64 (1.02-2.67)	0.047	257	1.24 (0.84-1.83)	0.28
III+IV	90	1.85 (0.86-3.99)	0.11	90	2.02 (1.01-4.01)	0.041
Stage T
1	180	1.57 (0.87-2.85)	0.13	180	0.73 (0.44-1.23)	0.24
2	94	0.55 (0.25-1.88)	0.12	94	0.6 (0.32-1.18)	0.11
3	78	2.51 (0.98-6.43)	0.047	78	2.68 (1.2-6.43)	0.013
Grade
1	55	0.56 (0.2-1.58)	0.27	55	1.81 (0.72-4.54)	0.2
2	177	0.16 (0.86-2.42)	0.16	177	1.57 (1.01-2.44)	0.043
3	122	1.64 (0.9-2.98)	0.11	122	1.33 (0.75-2.34)	0.32
Race
White	184	0.75 (0.47-1.2)	0.23	184	1.33 (0.89-1.98)	0.16
Asian	158	1.87 (1.03-3.38)	0.035	158	1.55 (0.86-2.8)	0.14
Sorafenib treatment
Treated	30	5.37 (1.37-21.12)	0.0081		6.42 (2.37-17.4)
Hepatitis virus
Yes	153	2.12 (1.11-4.05)	0.019	153	1.19 (0.71-2)	0.5
None	169	0.82 (0.52-1.3)	0.4	169	1.5 (0.97-2.31)	0.067
Alcohol consumption
Yes	117	1.64 (0.85-3.12)	0.13	117	1.52 (0.91-2.56)	0.11
None	205	1.7 (1.05-2.07)	0.028	205	1.34 (0.87-2.08)	0.18